{{Rsnum
|rsid=2975226
|Gene=SLC6A3
|Chromosome=5
|position=1445501
|Orientation=plus
|GMAF=0.4013
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=SLC6A3
}}{{PharmGKB
|RSID=rs2975226
|Name_s=
|Gene_s=SLC6A3
|Feature=NA
|Evidence=PubMed ID:18802919
|Annotation=A study in 243 children with ADHD and their parents suggests a role for the promoter region of the SLC6A3 gene in ADHD susceptibility. In the DSM-IV combined subtype, results showed a preferential transmission of the haplotype A/C/C/C/A derived from five SNPs (rs2550948, rs11564750, rs261759, rs2652511, rs2975223) in 5' region of the SLC6A3 gene.
|Drugs=
|Drug Classes=
|Diseases=Attention Deficit Disorder with Hyperactivity
|Curation Level=Curated
|PharmGKB Accession ID=PA162355587
}}
{{PMID Auto
|PMID=19879111
|Title=Association of promoter variants of human dopamine transporter gene with schizophrenia in Han Chinese
}}{{PMID Auto
|PMID=17630406
|Title=Dopamine genes and schizophrenia: case closed or evidence pending?
|OA=1
}}

{{PMID Auto
|PMID=19196467
|Title=Association study of promoter polymorphisms at the dopamine transporter gene in Attention Deficit Hyperactivity Disorder.
|OA=1
}}

{{PMID Auto
|PMID=20580759
|Title=Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia.
}}{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2975226
|overall_frequency_n=2
|overall_frequency_d=12
|overall_frequency=0.166667
|n_genomes=3
|n_genomes_annotated=0
|n_haplomes=4
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}